Cargando…

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism

The small-molecule drug voriconazole (VRC) shows a complex and not yet fully understood metabolism. Consequently, its in vivo pharmacokinetics are challenging to predict, leading to therapy failures or adverse events. Thus, a quantitative in vitro characterization of the metabolism and inhibition pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schulz, Josefine, Thomas, Antonia, Saleh, Ayatallah, Mikus, Gerd, Kloft, Charlotte, Michelet, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948939/ https://www.ncbi.nlm.nih.gov/pubmed/35335853 http://dx.doi.org/10.3390/pharmaceutics14030477

Ejemplares similares

Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide
por: Schulz, Josefine, et al.
Publicado: (2022)

Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans
por: Schulz, Josefine, et al.
Publicado: (2022)

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
por: Kluwe, Franziska, et al.
Publicado: (2023)

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion
por: Nassar, Yomna M., et al.
Publicado: (2022)

Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
por: Seeger, Johanna, et al.
Publicado: (2021)

A Model-Based Pharmacokinetic/Pharmacodynamic Analysis of the Combination of Amoxicillin and Monophosphoryl Lipid A Against S. pneumoniae in Mice
por: Franck, Sebastian, et al.
Publicado: (2021)

Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats
por: Shen, Jiquan, et al.
Publicado: (2020)

Impact of polymorphisms of pharmacokinetics‐related genes and the inflammatory response on the metabolism of voriconazole
por: Aiuchi, Naoya, et al.
Publicado: (2022)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Response Exemplified by Levofloxacin
por: Busse, David, et al.
Publicado: (2021)

Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats
por: Lee, Ji-Sang, et al.
Publicado: (2021)

Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization
por: Zhang, Yahui, et al.
Publicado: (2021)

Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization
por: Li, SiChan, et al.
Publicado: (2022)

Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
por: Jiang, Zhiwen, et al.
Publicado: (2022)

Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
por: Michelet, Robin, et al.
Publicado: (2023)

Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients
por: Busse, David, et al.
Publicado: (2021)

The pharmacokinetic challenge of voriconazole therapy for cerebral aspergillosis in patients treated with ibrutinib
por: Nyga, Rémy, et al.
Publicado: (2019)

Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review
por: Démaris, Alix, et al.
Publicado: (2022)

Inflammation Affects Liver Function and the Metabolism of Voriconazole to Voriconazole-N-Oxide in Adult and Elderly Patients
por: Liang, Zaiming, et al.
Publicado: (2022)

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
por: Busse, David, et al.
Publicado: (2021)

Application of different pharmacokinetic models to describe and predict pharmacokinetics of voriconazole in magellanic penguins following oral administration
por: Parsley, Ruth A., et al.
Publicado: (2018)

Impact of Albumin and Omeprazole on Steady-State Population Pharmacokinetics of Voriconazole and Development of a Voriconazole Dosing Optimization Model in Thai Patients with Hematologic Diseases
por: Khan-asa, Buddharat, et al.
Publicado: (2020)

Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
por: Shi, Hui-Yan, et al.
Publicado: (2010)

Predicting the Outcome of Voriconazole Individualized Medication Using Integrated Pharmacokinetic/Pharmacodynamic Model
por: Yang, Ping, et al.
Publicado: (2021)

CYP3A and CYP2C19 Activity Determined by Microdosed Probe Drugs Accurately Predict Voriconazole Clearance in Healthy Adults
por: Muhareb, Amin, et al.
Publicado: (2023)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
por: Chung, Hyewon, et al.
Publicado: (2015)

Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study
por: Suetsugu, Kimitaka, et al.
Publicado: (2021)

Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Pharmacokinetics and Safety of Two Voriconazole Formulations after Intravenous Infusion in Healthy Korean Volunteers
por: Cho, Sang-Heon, et al.
Publicado: (2020)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review
por: van Dyk, Madelé, et al.
Publicado: (2022)

The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups—An Investigation Using Physiologically Based Pharmacokinetic Modelling
por: Allegaert, Karel, et al.
Publicado: (2022)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
Publicado: (2023)

Response of chromoblastomycosis to voriconazole
por: de Lima, Alexandre Moretti, et al.
Publicado: (2016)

Serum voriconazole level variability in patients with hematological malignancies receiving voriconazole therapy
por: Saini, Lalit, et al.
Publicado: (2014)

Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
por: Krippendorff, Ben-Fillippo, et al.
Publicado: (2009)

Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity
por: Wiebe, Sabrina T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_frobqt1mpf1trl5hl0p1uvq017